vhh

VHH antibodies, or sdAbs, combine stability and specificity. Biointron explores their camelid origin and their growing role in biotech and medicine.

Antibody drug development has revolutionized biomedicine. Biointron highlights stages from discovery to approval that shape antibody-based therapies.

Learn about VHH libraries, including their creation, screening methods, structural diversity, and how nanobody technology supports research, diagnostics, and therapeutics.

Innovative antibody formats like VHHs, scFvs, and ADCs expand therapeutic options. Biointron explores how these formats drive flexibility and efficacy.

VHH antibodies, also known as nanobodies, are single-domain antibodies that are derived from camelid heavy-chain antibodies. Due to their small size (~ 15 kDa) and diverse applications in bio-derived therapeutics, these antibodies have widespread attention in the research and development community, with some examples below from just this week!

VHH antibodies offer stability, small size, and strong binding. Biointron highlights their promise in diagnostics, therapeutics, and next-generation antibody design.

VHH antibodies have reshaped biotech. Biointron reviews their discovery, unique advantages, and applications driving innovation in diagnostics and therapeutic development.

Learn about VHH antibodies, their history, diagnostic and therapeutic applications, and their role in advanced platforms like ELISA, biosensors, and targeted medicine.

Automation transforms antibody workflows. Discover robotic systems and integrated platforms that raise throughput, consistency, and data confidence.

The alpaca advantage: VHH discovery powered by unique immune repertoires. See how Biointron leverages alpaca libraries for robust nanobody identification.

Learn how antibody fragmentation enhances research and therapy using Fab, scFv, and VHH fragments for targeted drug delivery, diagnostics, and tissue penetration.

Explore ethical questions around antibody production in animals, the 3Rs principle, and how recombinant technology reduces animal use while ensuring high-quality science.

VHH combine small size with big performance—excellent stability, deep tissue access, and easy formatting—making them powerful tools for research and therapy.

Biointron has developed a successful method for discovering alpaca VHH for over 200 projects, using flexible immunization strategies and a robust phage display screening platform.